Panelists discuss how understanding EGFR mutations has transformed the treatment landscape for non–small cell lung cancer ...

In EGFR-mutated advanced NSCLC, first line osimertinib plus platinum-pemetrexed prolonged overall survival versus monotherapy ...

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients[i] New findings from this investigational study build on the strength of the data for amivantamab in ...

BERLIN -- Almost half of patients with advanced ALK -positive non-small cell lung cancer (NSCLC) have lived 7 years or longer ...

Combining osimertinib with LCT significantly improved PFS in metastatic EGFR-mutant NSCLC, reducing disease progression risk by 34%. The trial showed enhanced PFS across different EGFR mutation ...

Tagrisso combined with chemotherapy improved overall survival in EGFR-mutated NSCLC patients, including those with poor ...

Legendary actor and philanthropist William Shatner has joined forces with IdentifySensors Biologics, a pioneer in digital molecular diagnostics, to announce that the company has raised more than $20 ...

Black Diamond Therapeutics focuses on silevertinib, a next-gen EGFR inhibitor for NSCLC, after outlicensing its other lead asset to Servier.

There was strong uptake of Rybrevant-Lazcluze in first-line advanced, EGFR-mutated NSCLC after the combo bested AstraZeneca's Tagrisso in the MARIPOSA trial.

The final, formatted version of the article will be published soon. Circulating tumor cells (CTCs) hold promise for use in personalized medicine for hepatocellular carcinoma (HCC). Their abundance and ...